Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Phase 1/2 Completed 69 enrolled National Cancer Institute (NCI)

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Erlotinib and temsirolimus and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of temsirolimus when given together with erlotinib and to see how well they work in treating patients with recurrent malignant glioma.

Timeline

Start: 2005-04
Primary completion: 2010-04
Completion: 2014-04

Publications

Results Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	150 mg	Oral
Subject	Temsirolimus	Small molecule	15 mg	Intravenous
Subject	Temsirolimus	Small molecule	50 mg	Intravenous

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Summary

Timeline

Publications

Drugs

Indications